Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.

Bullfrog AI Holdings, Inc. Common Stock

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

JOINT ONCOLOGY CONFERENCE SUBMISSION PLANNED AND FOLLOW-ON CONTRACT DISCUSSION UNDERWAY VALIDATES BULLFROG AI'S ENTERPRISE-GRADE PLATFORM STRATEGY, COMBINING AUTOMATION AND HUMAN-IN-THE-LOOP OVERSIGHT FOR SCALABLE, TRUSTWORTHY ANALYTICS GAITHERSBURG, MD., SEPT. 08, 2025 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC.(NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY PROVIDED AN UPDATE ON ITS COLLABORATION WITH ELEISON PHARMACEUTICALS INC. (ELEISON), A PHASE 3 ONCOLOGY COMPANY FOCUSED ON NOVEL CHEMOTHERAPEUTIC TREATMENTS FOR RARE CANCERS.

BULLFROG AI'S BFPREP AND BFLEAP PLATFORMS DELIVER REAL-WORLD IMPACT IN ELEISON PHARMACEUTICALS COLLABORATION

GAITHERSBURG, MD., JULY 28, 2025 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC.(NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE ("AI") AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY ANNOUNCED THAT VIN SINGH, CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AND ONE-ON-ONE MEETINGS AT BTIG'S ANNUAL VIRTUAL BIOTECHNOLOGY CONFERENCE, BEING HELD TUESDAY, JULY 29THROUGH WEDNESDAY, JULY 30.

BULLFROG AI TO PRESENT AT BTIG ANNUAL VIRTUAL BIOTECHNOLOGY CONFERENCE

FROM TARGET DISCOVERY TO TRIAL OPTIMIZATION, BFLEAP EMPOWERS BIOPHARMA TEAMS TO PREDICT THERAPEUTIC SUCCESS WITH GREATER CONFIDENCE

RETHINKING R&D: BULLFROG AI WHITE PAPER OUTLINES NEW BLUEPRINT FOR SMARTER DRUG DEVELOPMENT

GAITHERSBURG, MD., JUNE 20, 2025 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC.(NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY ANNOUNCED THAT DR. JUAN FELIPE BELTRN, DIRECTOR OF AI, MACHINE LEARNING, AND INNOVATION, WILL BE THE FEATURED SPEAKER AT THE UPCOMING XTALKS WEBINAR: AI IN BIOINFORMATICS: OVERCOMING PITFALLS IN STATISTICAL, ML AND GENERATIVE AI APPROACHES.

BULLFROG AI'S DR. JUAN FELIPE BELTRN TO HIGHLIGHT ADVANCED AI STRATEGIES IN BIOINFORMATICS AT XTALKS WEBINAR

GAITHERSBURG, MD., JUNE 12, 2025 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC.(NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY ANNOUNCED A STRATEGIC COLLABORATION WITH SYGNATURE DISCOVERY, A LEADING UK-BASED CONTRACT RESEARCH ORGANIZATION (CRO) SPECIALIZING IN DRUG DISCOVERY. THROUGH THIS COLLABORATION, SYGNATURE WILL INTRODUCE BULLFROG DATA NETWORKSBULLFROG'S PROPRIETARY AI-DRIVEN DATA INSIGHTS PLATFORM POWERED BY THE BFLEAP ENGINETO SYGNATURE'S GLOBAL CLIENT BASE OF RELEVANT BIOPHARMA COMPANIES.

BULLFROG AI ANNOUNCES STRATEGIC COLLABORATION WITH SYGNATURE DISCOVERY TO INTRODUCE BULLFROG DATA NETWORKS TO GLOBAL BIOPHARMA CLIENTS

GAITHERSBURG, MD., DEC. 27, 2024 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, ISSUED A LETTER TO STOCKHOLDERS FROM ITS CEO VIN SINGH.

BULLFROG AI ISSUES LETTER TO STOCKHOLDERS

GAITHERSBURG, MD., DEC. 17, 2024 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY ANNOUNCED THE APPOINTMENT OF JOSH BLACHER AS ITS CHIEF FINANCIAL OFFICER (CFO), EFFECTIVE IMMEDIATELY. THIS APPOINTMENT COMES IN THE WAKE OF THE UNTIMELY PASSING OF DANE SAGLIO, BULLFROG AI'S FORMER CFO, WHO RECENTLY LOST HIS BATTLE WITH CANCER.

BULLFROG AI ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

GAITHERSBURG, MD., OCT. 22, 2024 (GLOBE NEWSWIRE) -- BULLFROG AI, INC. (NASDAQ: BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, TODAY ANNOUNCED ITS VP ARTIFICIAL INTELLIGENCE, ENRIQUE GARCA-RIVERA, PH.D., WILL PRESENT AT GOOGLE'S INAUGURAL CANCER AI SYMPOSIUM ON OCTOBER 30, 2024, AT THE BOSTON CENTER FOR THE ARTS.

BULLFROG AI'S VP ARTIFICIAL INTELLIGENCE TO PRESENT AT GOOGLE'S CANCER AI SYMPOSIUM

JERSEY CITY, N.J. , OCT. 21, 2024 /PRNEWSWIRE/ -- WALLACHBETH CAPITAL LLC, A LEADING PROVIDER OF CAPITAL MARKETS AND INSTITUTIONAL EXECUTION SERVICES, ANNOUNCED THAT -- BULLFROG AI HOLDINGS, INC. (NASDAQ:BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, ANNOUNCED TODAY IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED DEFINITIVE AGREEMENT FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 1,565,000 SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) IN A REGISTERED DIRECT OFFERING AND, IN A CONCURRENT PRIVATE PLACEMENT, COMMON WARRANTS TO PURCHASE UP TO 1,565,000 SHARES OF COMMON STOCK (TOGETHER WITH THE REGISTERED DIRECT OFFERING) AT A COMBINED PURCHASE PRICE OF $2.00.

WALLACHBETH CAPITAL ANNOUNCES CLOSING OF BULLFROG AI REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT FOR AGGREGATE GROSS PROCEEDS OF $3.13 MILLION

GAITHERSBURG, MD., OCT. 21, 2024 (GLOBE NEWSWIRE) -- BULLFROG AI HOLDINGS, INC. (NASDAQ:BFRG; BFRGW) ("BULLFROG AI" OR THE "COMPANY"), A TECHNOLOGY-ENABLED DRUG DEVELOPMENT COMPANY USING ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING TO ENABLE THE SUCCESSFUL DEVELOPMENT OF PHARMACEUTICALS AND BIOLOGICS, ANNOUNCED TODAY IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED DEFINITIVE AGREEMENT FOR THE PURCHASE AND SALE OF AN AGGREGATE OF 1,565,000 SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) IN A REGISTERED DIRECT OFFERING AND, IN A CONCURRENT PRIVATE PLACEMENT, COMMON WARRANTS TO PURCHASE UP TO 1,565,000 SHARES OF COMMON STOCK (TOGETHER WITH THE REGISTERED DIRECT OFFERING) AT A COMBINED PURCHASE PRICE OF $2.00. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $2.00 PER SHARE, ARE INITIALLY EXERCISABLE ON THE DATE THAT IS SIX MONTHS FROM THE DATE OF ISSUANCE AND WILL EXPIRE FIVE YEARS FROM SUCH INITIAL EXERCISE DATE.

Bullfrog AI Holdings, Inc. Common Stock

BFRG

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Bullfrog AI Holdings, Inc. Common Stock

BFRG.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BFRG